• About us
    About us

    Zealand Pharma is an international biotechnology company headquartered in Denmark, with operations in Boston, USA. We are focused on the discovery, design, and development of innovative peptide-based and small molecule medicines that empower people to live long and healthy lives

  • Learn More About us Overview
  • Peptide expertise
  • Partnering
  • Corporate management
  • Board of Directors
  • Corporate governance
  • Our impact
  • Reports & policies
  • Disease areas
    Disease areas

    Zealand Pharma is focused on disease areas where we believe we can transform metabolic health and deliver outcomes that increase human healthspan​

  • Learn More Disease areas Overview
  • Obesity
  • Congenital Hyperinsulinism
  • Short Bowel Syndrome
  • Chronic Inflammation
  • Pipeline
    Pipeline

    At Zealand Pharma, we aim to build the world’s most valuable metabolic health pipeline, underpinned by our portfolio of novel and differentiated candidates

  • Learn More Pipeline Overview
  • Petrelintide
  • ZP6590
  • Survodutide
  • Dasiglucagon: Continuous infusion
  • Glepaglutide
  • ZP9830
  • Petrelintide / CT-388
  • Dapiglutide (program paused)
  • Scientific publications
  • Investors
    Investors

    Zealand Pharma is committed to creating value for our society and our shareholders through life-changing peptide therapeutics for people who need them.

  • Learn More Investors Overview
  • Shareholder portal
  • Stock information
  • Financial reports
  • Events & presentations
  • Annual General Meeting
  • Analyst coverage
  • FAQs
  • PFIC Annual Information
  • Extraordinary General Meeting May 2026
  • Zealand Pharma represents a unique investment opportunity Download presentation
  • News & media
    News & media

    Zealand Pharma provides news through company announcements and press releases.

  • Learn More News & media Overview
  • Newsroom
  • Media resources
  • Subscribe to news
  • Careers
    Careers

    At Zealand Pharma we pride ourselves on the way we work together as one team fostering a strong and engaging company culture founded on collaboration, courage, empowerment, and trust.

  • Learn More Careers Overview
  • Values and culture
  • Meet the Zealanders
  • Interested in a career at Zealand Pharma? View open positions
  • Contact
    Contact
  • Learn More Contact Overview
  • Compliance Hotline
  • Investors
  • Stock information
  • Stock information

  • Share Price
  • Stock Information
  • Subscribe
  • Share price

    • ZEAL (COP)

      280.70DKK
    • CHANGE

      +28.40
    • CHANGE

      +11.26%

    Last updated on 09 June 2026 14:19 (GMT +01:00)

    Zealand Pharma 1503

    Stay up-to-date with the latest news from Zealand

    Sign up to receive press releases and important company announcements directly to your inbox

    Subscribe

    For general investor inquiries, please fill out our contact form

  • Get in touch
  • Company

  • About us
  • Investors
  • News & Media
  • Careers
  • Contact
  • Compliance Hotline
  • Disease Areas

  • Obesity
  • Congenital Hyperinsulinism
  • Short Bowel Syndrome
  • Chronic inflammation
  • Pipeline

  • Petrelintide
  • Dapiglutide
  • ZP6590
  • Survodutide
  • Dasiglucagon: Continuous infusion
  • Glepaglutide
  • ZP9830
  • Follow us

  • LinkedIn
  • © ZEALAND PHARMA
  • Terms of use
  • Privacy notice
  • Accessibility
  • Cookie notice
  • Cookie settings
  • Designed & built by SampsonMay

    You are about to leave Zealand Pharma's website

    The link below goes to a website not owned by Zealand Pharma:
  • Continue to external site
  • Zealand Pharma does not endorse the content of any such third-party website